The activity of GR69153, a novel catechol-substituted cephalosporin, was compared with those of ceftazidime and ceftriaxone in a multicenter study against 5,203 fresh clinical isolates of gram-negative and gram-positive bacteria. GR69153 was generally very active at concentrations equivalent to or two-to fourfold lower than those of ceftazidime and ceftriaxone against gram-negative bacilli other than Citrobacterfreundii, Enterobacter cloacae, and Xanthomonas maltophiia. Against Pseudomonas aeruginosa, MICs of GR69153 and ceftazidime for 50% of isolates tested (MIC50s) were, respectively, 1 and 2 ,ug/ml; the corresponding MIC90s were 4 and 16 ,ug/ml. Although MIC50s of GR69153 for staphylococci were two-to eightfold lower than those of ceftazidime or ceftriaxone, MIC90s against staphylococci and enterococci were .16 ,ug/ml for all three compounds. Quality control MIC ranges for reference strains are proposed for the broth microdilution method on the basis of the GR69153 data derived from this multicenter study.
GR69153 is a novel catechol-substituted parenteral cephalosporin that is actively transported into gram-negative cells via iron-regulated outer membrane proteins (6) . It is generally two-to fourfold more active in vitro than ceftazidime against gram-negative bacteria (1). Erwin et al. (1) reported frequent resistance to GR69153 among gram-negative bacilli that are most frequently associated with stably derepressed type I ,-lactamase, as well as among isolates of Xanthomonas maltophilia. The antistaphylococcal activity of GR69153 is comparable to or somewhat better than those of other expanded-spectrum cephalosporins (1), but it is somewhat less than that of cefazolin (2) .
The purposes of this study were to compare the activity of GR69153 with those of ceftazidime and ceftriaxone in a multicenter study and to establish quality control (QC) parameters for the broth microdilution test on the basis of data derived from testing of the reference strains which are recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (4). The QC study design was in accord with NCCLS guidelines on the development of in vitro testing criteria and QC parameters (5 a Includes E. amnigenus (two strains), E. geogoviae (two strains), E. sakazakii (four strains), E. taylorae (four strains), and E. vulneris (two strains).
b Includes S. liquefaciens (six strains), S. odorifera (two strains), and S. rubidaea (two strains).
Includes Citrobacter amalonaticus (six strains), Escherichia hermannii (four strains), Hafnia alvei (two strains), Kluyvera spp. (four strains), Proteus penneri (two strains), Providencia alcalifaciens (two strains), Persinia stuartii (six strains), Salmonella enteritidis (six strains), Shigella sonnei (two strains), and Yersinia enterocolitica (two strains).
d Includes P. fluorescens (three strains), P. picketti (one strain), P. putida (three strains), P. stutzeri (six strains), and Pseudomonas spp., (five strains). e Includes Achromobacter xylosoxidans (three strains), Aeromonas hydrophila (four strains), and one strain each for Agrobacterium radiobacter, Alcaligenes spp., Bordetella brochoseptica, CDC group VA, Pasteurella haemolyticus, and Pasteurella multocida. and for oxacillin-susceptible Staphylococcus epidermidis to be 0.25 and 0.5 ,.ug/ml, respectively (2) . In contrast, MIC90s for oxacillin-resistant staphylococci were >128 jig/ml (2) .
GR69153 MICs for Streptococcus agalactiae were 1 ,ug/ml for both GR69153 and ceftazidime and 0.25 j,g/ml for ceftriaxone ( Table 2) . Reference QC strains were tested in each study center on at least 20 occasions over a minimum of 5 In conclusion, GR69153 had activity in vitro equivalent to or exceeding those of ceftazidime and ceftriaxone against gram-negative bacilli. Its activity against staphylococci was generally equivalent to those of ceftazidime and ceftriaxone. The complete relationships between the in vitro and in vivo activities of catechol-substituted cephalosporins such as GR69153 remain to be investigated.
